Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
Launched by EVERGREEN GENERAL HOSPITAL, TAIWAN · Nov 7, 2021
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether the overall adenoma detection rate (ADR) during a colonoscopy can be a good substitute for the screening adenoma detection rate. Essentially, researchers want to find out if measuring how well doctors find adenomas (which are growths that can sometimes turn into cancer) during colonoscopies for various reasons—like checking for cancer or monitoring existing issues—can replace the specific detection rate used for screening purposes alone.
To be part of this study, you need to be at least 50 years old and scheduled for a colonoscopy. However, certain individuals are not eligible, including those with specific family histories of colorectal cancer, certain syndromes, or other serious conditions affecting the colon. If you join the study, you can expect to undergo a routine colonoscopy, and your results will help researchers determine the best ways to detect adenomas in the future. It’s important to know that the study is currently looking for participants, and your involvement would contribute valuable information to improve colorectal health practices.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • consecutive patients aged ≥50 years undergoing colonoscopy are eligible for enrollment.
- Exclusion Criteria:
- • high risk family history of colorectal cancer (CRC) e.g., familial adenomatous polyposis, hereditary non-polyposis CRC syndrome, multiple first degree relatives with CRC, or a single first degree relative with CRC at \<60 years
- • serrated polyposis syndrome
- • inflammatory bowel disease
- • colonoscopy to remove a large neoplastic polyps
- • obstructive lesions of the colon
- • gastrointestinal bleeding
- • current participation in other studies
- • hospitalized patients
- • mental retardation
- • pregnancy
- • refusal to provide a written informed consent.
About Evergreen General Hospital, Taiwan
Evergreen General Hospital, located in Taiwan, is a leading healthcare institution dedicated to advancing medical research and clinical innovation. With a strong commitment to patient care and safety, the hospital actively sponsors clinical trials aimed at evaluating new treatments and interventions across various medical disciplines. Leveraging a multidisciplinary team of experienced clinicians and researchers, Evergreen General Hospital fosters a collaborative environment that promotes groundbreaking studies and enhances the understanding of healthcare practices. The institution adheres to the highest ethical standards and regulatory guidelines, ensuring rigorous trial design and execution to contribute valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kaohsiung, , Taiwan
Taoyuan, , Taiwan
Taoyuan, , Taiwan
Keelung, , Taiwan
North Hills, California, United States
Kaohsiung, , Taiwan
Patients applied
Trial Officials
Chi-Liang Cheng
Principal Investigator
Evergreen General Hospital, Taoyuan, Taiwan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials